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Introduction
Cardiovascular medicine has, in general, enthusiastically embraced
new technologies and used them per appropriate guidelines.
However, one area in which this has not been as much the case
has been with cardiac troponin (cTn). There has been reluctance
to use cTn at the suggested 99th percentile of the upper reference
range (URL).1 Part of this reluctance reflects a lack of comfort with
the large number of increases seen with such a sensitive probe that
challenge clinicians.2 However, the reluctance to utilize cTn prop-
erly has distorted the utility of cTn in many areas,1,2 but perhaps it
has caused the greatest confusion in the area of post-PCI biomark-
er increases as attested to by recent articles.3– 5 In this area, the
reluctance to give up the paradigms of the past and to use cTn
per guidelines has led to confusion and inaccurate conclusions in
articles published even in our most prestigious journals. This edi-
torial from a group of researchers knowledgeable in this area
attempts to articulate some of the difficulties with the interpreta-
tions thus far posed and suggest how proper use of cTn can
achieve a better understanding in this important area. It does not
and cannot answer all of the questions going forward but progress
is only possible if we understand and properly interpret the data
that presently exist.
A recent article in this area published in JACC3 is an excellent
example of the problems in this area. It was followed by an editorial
that misconstrues most of the important concepts.4 The article uti-
lized MR imaging post-PCI to visualize areas of cardiac injury puta-
tively related to the procedure. Because they used a good and
sensitive cTn assay and the recommended cut-off values, they
found that more increases in CK-MB were associated findings of
delayed hyperenhancement than with cTn. However, they then con-
cluded that CK-MB increases were more significant. The problems
with this logic are several. First, it is not surprising that increases
of CK-MB are more apt to be detected by MR imaging; CK-MB is
much less sensitive than cTn and so more myocardial injury is
required and thus MR imaging detects larger areas of hyperenhance-
ment. The authors acknowledge this in the results section by indicat-
ing that higher cTn values would have provided similar results to
CK-MB. Does that mean that the increases of cTn not seen were
not related to cardiac injury? Of course not! MR imaging is less sen-
sitive than cTn and therefore patients with small increase in cTn may
not manifest hyperenhancement. The only challenge to this assertion
utilized a very insensitive cTn assay and an excessively high cut-off
value6 that was unmasked by calling the authors (A.S.J. personal
communication). In addition, if plaque emboli are the aetiology of
the injury, it may be sufficiently diffuse that it does not cause hyper-
enhancement because the areas of injury are not sufficiently conflu-
ent.7 Finally, we have no data to suggest that MR detectable defects
worsen prognosis more than non detectable ones.
Most importantly, we contend that present data do not support
the contention that post-PCI biomarker increases imply an adverse
prognosis when the analysis includes the baseline cTn value used as
suggested by guidelines.8 This later point underlies the confusion
articulated in the JACC editorial.4 The concept of post-PCI
injury developed prior to the development of cTn. The initial
studies suggested that if one had a normal CK-MB at baseline
and then an increase post-intervention, it was associated with an
adverse prognosis.9 We do not take issue with the design or inter-
pretation of those studies, but would point out that there was con-
troversy at the time about how minor amounts of necrosis could
cause an adverse prognosis.10 In hindsight, those concerns were
more right than wrong and now the use of cTn has helped us to
understand the reason for the results that were reported. In
most of the initial studies, the likelihood of a stable baseline
value was presumed but, in retrospect, it is clear that was improb-
able because so many of the patients presented acutely. Now, with
acute presentations, in many patients cTn measurements are
already rising.11 Knowing that cTn is rising confirms what is difficult
to ascertain with CK-MB; that it, too, likely is rising. Thus, what was
called a normal CK-MB in these studies belied the fact that the
value was already starting to rise, albeit slowly and from a relatively
low baseline.
Cardiac troponin solves this problem but only if one interprets
the values properly. If one uses high cut-off values for the baseline,
this effect may be missed. However, once it is recognized that the
baseline value is rising, it becomes clear that distinguishing
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subsequent rises from the initial insult from those due to PCI is im-
possible regardless which biomarker one uses. The use of the
proper reference value at baseline is essential to detect this situ-
ation. Some data suggest that most post-PCI increases are due
to increases induced prior to the PCI because it is almost exclu-
sively those who have increased cTn at baseline who manifest
marked increases (greater than three-fold) of either cTn or
CK-MB post-PCI.11 Thus, perhaps most of the myocardial injury
is related to the initial insult although it is hard to exclude an add-
itional component due to re-perfusion of an already injured area or
due to new interventional complications.12,13 An appreciation of
this fact has been lost in many studies because so many studies
have not used the recommended cut-off values at baseline (see
below). One could of course argue that any increase is adverse,
but the critical question is at what level, if any, does it become clin-
ically significant (see below).
It is well understood that, in patients with ACS, an increased cTn
marks patients at accentuated risk.14 cTn increases mark more
adverse coronary anatomy, more unstable plaque, more throm-
bosis, more endothelial dysfunction, or all in combination.14 Re-
cently, similar data in patients with stable disease have been
presented; i.e. increases of cTn are common and prognostically im-
portant with or without intervention.15,16 Consequently, the infor-
mation provided by cTn is available prior to PCI. Because CK-MB is
less sensitive, increases lag behind cTn so some of CK-MB
increases are only detectable post PCI. Appreciation of this prog-
nostic information at baseline critically depends on the use of the
proper cut-off value (the 99th percentile URL) because this value
maximizes the prognostic value. Values above this and many below
are indicative of myocardial injury because most assays cannot
measure normal values.8 If one uses a higher cut-off value, one
diminishes this prognostic effect. A good example of this is a
recent analysis using the value at the 10% coefficient of variation
(CV) instead of the 99th percentile value. This value is higher
than the 99th percentile URL. In a large cohort with baseline
values ,10% of the CV value, increases rising to above that
value were reported to have prognostic importance.17 However,
these values are abnormal and likely were rising pre-PCI and
there is known prognostic significance to this value as well.18
With high-sensitivity assays, we now know that values in that
range are well above the true normal values. Unfortunately, the
use of cut-off values above the 99th percentile value to define a
‘normal’ baseline value is common practice. In one recent
meta-analysis,5 it was claimed that all the baseline values were
‘normal,’ but if one reviews the individual manuscripts, none of
the papers cited used the 99th percentile value with a reasonably
sensitive cTn assay. It was not until 2008 that an analysis using the
99th% URL was reported.19 When the 99th percentile cutoff was
used to determine a normal baseline, increases at baseline above
this level provided substantial prognostic information but neither
values of cTn nor CK-MB post-PCI regardless of their magnitude
had prognostic significance. The only marginally significant analysis
was the short-term analysis of patients with normal values (less
than the 99th percentile value) at baseline and isolated increases
of cTn post-PCI. The P-value for a short-term adverse prognostic
sign was 0.05. However, 2/3 of the events in this group occurred
secondary to non-cardiac causes in patients with severe non-
cardiac co-morbidities. There was no signal for cardiac complica-
tions. The recent analysis by Cavellini is similar despite the fact
that they used a cut-off value slightly higher than the 99th percent-
ile.20 The lack of prognostic value of post-PCI biomarker increases
also recently was reported from the Acuity trial.21 What this
means is that interventional cardiologists have been at least partial-
ly right in saying that a good intervention, even if associated with
small amounts of necrosis, is not associated with an adverse prog-
nosis. Most importantly, well-done interventions in the absence of
baseline injury rarely results in marked increases in biomarkers. It is
only when treating a recently damaged area that more marked
increases occur and they may be due mostly to the initial insult
and not the intervention. What is associated with an adverse prog-
nosis is more severe disease, which is what an increased biomarker
at baseline denotes. The necessary prognostic information is avail-
able at baseline if one uses the proper metrics. Thus, in our
opinion, CK-MB no longer has a role in defining post-PCI injury.
For now, cTn at baseline will provide all the prognostic information
that is important. It is likely that there is some level of post-PCI cTn
increase, where a peri-procedural complication harms patients but
the frequency of those marked increases are likely infrequent and
hard to study. One could argue that physicians should continue to
monitor cTn post-procedures for quality control purposes but not
prognosis.
As with any field, there are many questions posed by new data
and/or new interpretations of older data. This is certainly the case
here. We would point out the need to define the following:
(1) There are data sets that could probe the frequency where a
peri-procedural myocardial infarction (AMI) might have been
diagnosed despite the fact that PCI was delayed.
(2) Other investigators could reanalyse their data sets using con-
temporary assays and proper cut-off values to confirm or
refute our synthesis.
(3) We suspect that novel high-sensitivity cTn assays will support
the prior data detailed. However, this will only happen if the
proper metrics are used.
(4) There are some patients who have stable increases of cTn
either due to chronic disease or because they are on the
down slope of the cTn time–concentration curve after an
event. The impact of a subsequent rise after PCI has not yet
been defined in this group.
(5) It may well be that if identical interventions were done, it might
be that those without any injury at all (no cTn change) might
have a better prognosis since any loss of myocardium is prob-
ably adverse. However, it might take hundreds of thousands of
patients to confirm this but it should be explored. Perhaps
very large data sets will allow us to define some level at
which elevated post-PCI values are prognostically important
even when they occur from a normal baseline value.
(6) Using post-PCI cTn increases to probe the effects of new
adjunctive interventions might be a wise investment in the
future.
(7) We should ask if increases in cTn post-procedure is of import-
ance in other developing catheter-based interventions?
In conclusion, it is time to move beyond the concept that post-PCI
CK-MB values are useful. Furthermore, it is time to give up the
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concept that post-PCI myocardial injury is an important endpoint.
Some clinical trialists wish to retain it because it has served clinical
trials well for many years. However, from a patient-oriented focus,
prognostically, it is the increases of cTn at baseline that are import-
ant. Likely, further increases post-PCI are indicative of cardiac
injury if the baseline value is normal but the data strongly
support the idea that such increases rarely have prognostic import-
ance. Should we call these biomarker increases AMIs despite the
lack of prognostic significance? Should we measure biomarkers
post-PCI? If we choose to, what criteria should we employ? Our
focus should be on questions like this and not on trying to justifying
the retention of paradigms that no longer serve the clinical com-
munity well.
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